| Neuromyelitis Optica Spectrum Disorder |
ChiCTR-OPB-16007730: Mycophenolate Mofetil Treatment of Neuromyelitis Optica in Chinese Patients (MONICA) |
|
|
| Recruiting | 4 | 100 | | Mycophenolate Mofetil | The third affiliated hospital, Sun Yat-sen university; The third affiliated hospital, Sun Yat-sen university, Manufacturer of sponsorship | Neuromyelitis optica | | | | |
ChiCTR1900025744: Clinical effectiveness and safety of Rituximab (Henlius) for optic neuritis secondary to neuromyelitis optica spectrum disorder: a pilot clinical trial |
|
|
| Recruiting | 4 | 60 | | Intravenous 200mg Rituximab, 1/week*2, if the proportion of CD19+ B lymphocytes in peripheral blood is above 1% then repeat administration (200mg) ;Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (750～3000mg/day) | The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital; The General Hospital of Chinese Peoples Liberation Army, funded by the National Natural Science Fundation of China (NO.81870662) | neuromyelitis optica spectrum disorder （NMOSD） | | | | |
NCT05896605: Monitoring of Azathioprine Metabolite Concentrations and Cytokine Levels in Neuromyelitis Optica Spectrum Disorder |
|
|
| Completed | 4 | 63 | RoW | Azathioprine, Azathioprine Tablets | First Affiliated Hospital of Guangxi Medical University | NMO Spectrum Disorder, Azathioprine Adverse Reaction | 12/22 | 04/23 | | |
| Terminated | 4 | 4 | Europe, Canada, Japan, US, RoW | Satralizumab 120 mg | Hoffmann-La Roche, Chugai Pharmaceutical Co. | Neuromyelitis Optica Spectrum Disorder, NMOSD | 10/23 | 10/23 | | |
ChiCTR2100043013: Efficacy difference between low dose rituximab and mycophenolate mofetil in preventing recurrence of NMOSD |
|
|
| Not yet recruiting | 4 | 60 | | low dose rituximab ;mycophenolate mofetil | Shandong University Qilu Hospital; Shandong University Qilu Hospital, self-finance | Neuromyelitis optica spectrum diseases | | | | |
NCT06212245: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | 4 | 33 | RoW | Inebilizumab | Hansoh BioMedical R&D Company, Horizon Therapeutics Ireland DAC | Neuromyelitis Optica Spectrum Disorders | 12/24 | 06/25 | | |
| Recruiting | 4 | 30 | Europe, RoW | Blood tests, Inebilizumab, UPLIZNA | Amgen | Neuromyelitis Optica Spectrum Disorder | 06/28 | 06/28 | | |
2021-001088-26: A Clinical, Imaging and Biomarker Study in Neuromyelitis Optica Spectrum Disorder (NMOSD) with Satralizumab as an Intervention Studio clinico, di imaging e sui biomarcatori condotto nel disturbo dello spettro della neuromielite ottica (NMOSD) con Satralizumab come intervento |
|
|
| Not yet recruiting | 3 | 100 | Europe | satralizumab, [RO5333787], Solution for injection/infusion in pre-filled syringe, Enspryng | F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd, F. Hoffmann-La Roche Ltd | Neuromyelitis Optica Spectrum Disorder (NMOSD) Disturbo dello spettro della neuromielite ottica (NMOSD), NMOSD,also known as Devic disease, is a disorder of the brain and spinal cord dominated by inflammation of the optic nerve(optic neuritis)and inflammation of the spinal cord (myelitis). NMOSD,noto anche come malattia di Devic,è un disturbo del cervello e del midollo spinale dominato da infiammazione del nervo ottico (neurite ottica) e dall'infiammazione del midollo spinale (mielite)., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Active, not recruiting | 3 | 58 | Europe, Canada, Japan, US, RoW | Ravulizumab, ALXN1210, Ultomiris | Alexion | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | 03/22 | 07/24 | | |
2019-004092-39: A Study to Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, and Pharmacodynamics of Satralizumab in Pediatric Patients with Aquaporin-4 (AQP4) Antibody Positive Neuromyelitis Optica Spectrum Disorder |
|
|
| Not yet recruiting | 3 | 8 | Europe | Satralizumab, Ro 533-3787/F01- 06, Solution for infusion in pre-filled syringe, Enspryng | F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd | Neuromyelitis Optica Spectrum Disorder (NMOSD), NMOSD is a chronic disorder of the brain and spinal cord dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis)., Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT03330418: A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 3 | 166 | RoW | Placebo, RC18 160 mg | RemeGen Co., Ltd. | Neuromyelitis Optica Spectrum Disorders | 05/25 | 12/25 | | |
NCT04660539 / 2020-003413-35: A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD) |
|
|
| Completed | 3 | 119 | Europe, Canada, Japan, US, RoW | satralizumab, Enspryng, azathioprine (AZA), non-investigational medicinal product (NIMP), mycophenolate mofetil (MMF), NIMP, oral corticosteroids | Hoffmann-La Roche | Neuromyelitis Optica Spectrum Disorder | 05/24 | 05/24 | | |
AQUARELLE, NCT05730699: Efficacy and Safety of Divozilimab in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 3 | 105 | RoW | divozilimab, Placebo | Biocad | Neuromyelitis Optica Spectrum Disorders | 09/24 | 04/25 | | |
NCT05314010: A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 3 | 140 | RoW | MIL62, Placebo | Beijing Mabworks Biotech Co., Ltd. | Neuromyelitis Optica Spectrum Disorder | 03/25 | 03/27 | | |
SAkuraSun, NCT05199688: A Study To Evaluate Pharmacokinetics, Efficacy, Safety, Tolerability, And Pharmacodynamics Of Satralizumab In Pediatric Patients With Aquaporin-4 Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 3 | 8 | Europe, US, RoW | Satralizumab | Hoffmann-La Roche | Neuromyelitis Optica Spectrum Disorder, NMOSD | 03/27 | 09/29 | | |
2019-001829-26: A Trial to Evaluate the Safety and Activity of Eculizumab in PediatricPatients with Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD) Ensayo para evaluar la seguridad y actividad de eculizumab en pacientes pediátricos con trastorno del espectro de la neuromielitis óptica recidivante |
|
|
| Not yet recruiting | 2/3 | 15 | Europe | Soliris, Soliris, Concentrate for solution for infusion, Soliris | Alexion Pharmaceuticals Inc., ALEXION PHARMACEUTICALS INCORPORATED, Alexion Pharmaceuticals Inc, Alexion Pharmaceuticals Inc. | Neuromyelitis Optica Spectrum Disorder (NMOSD) Trastorno del espectro de la neuromielitis óptica (TENMO), Neuromyelitis Optica Spectrum Disorder (NMOSD) Trastorno del espectro de la neuromielitis óptica (TENMO), Diseases [C] - Nervous System Diseases [C10] | | | | |
ECU-NMO-303, NCT04155424: A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder |
|
|
| Terminated | 2/3 | 5 | Europe, Canada, Japan, US, RoW | Eculizumab, Soliris | Alexion Pharmaceuticals, Inc. | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder | 07/23 | 07/23 | | |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Not yet recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
DAWN, NCT05403138: Safety and Efficacy of Daratumumab in Patients With Anti-Aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2/3 | 72 | RoW | Daratumumab, Darzalex, Placebo | Tianjin Medical University General Hospital | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, NMO Spectrum Disorder | 08/24 | 10/24 | | |
| Recruiting | 2/3 | 12 | Europe, Canada, Japan, US, RoW | Ravulizumab, ALXN1210, Ultomiris | Alexion Pharmaceuticals, Inc. | Neuromyelitis Optica Spectrum Disorder | 03/26 | 03/28 | | |
| Not yet recruiting | 2 | 20 | | | St Vincent's Hospital, Sydney , St Vincent's Hospital,Sydney | Neuromyelitis Optica, Stiff Person Syndrome, Myasthenia Gravis, Central Nervous System Vasculitis | | | | |
NCT04614454: High Frequency Impulse Therapy for Neuropathic Pain in NMOSD |
|
|
| Active, not recruiting | 2 | 46 | US | High Frequency Impulse Therapy, Transcutaneous electrical nerve stimulation, High Frequency Impulse Therapy - Sham, Transcutaneous electrical nerve stimulation - Sham | Massachusetts General Hospital | Neuromyelitis Optica | 04/22 | 12/24 | | |
NCT04670770: An Open Label Study of the Effects of SHR1459 in NMOSDs Patients |
|
|
| Completed | 2 | 10 | RoW | Drug - SHR1459 | Reistone Biopharma Company Limited | Neuromyelitis Optica Spectrum Disorders | 08/22 | 08/22 | | |
CAMPUS, NCT04064944: Comparison of the Efficacy and Safety of Immunoadsorption and Plasma Exchange for Acute Attack of Refractory Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | 2 | 144 | NA | blood purification equipment | Third Affiliated Hospital, Sun Yat-Sen University, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong 999 Brain Hospital | Neuromyelitis Optica Spectrum Disorder | 08/23 | 12/24 | | |
| Recruiting | 2 | 20 | RoW | zanubrutinib | Xuanwu Hospital, Beijing | Neuromyelitis Optica | 10/24 | 10/24 | | |
NCT05551598: Efficacy and Safety of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD) |
|
|
| Not yet recruiting | 2 | 45 | NA | Mitoxantrone Hydrochloride Liposome Injection | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | Neuromyelitis Optica Spectrum Disorder | 10/24 | 04/25 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
SENS-NMO, NCT05974293: A Phase IIb Study of Nabiximols for Spasticity Due to Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | 2 | 44 | US | Nabiximols, Sativex, Placebo | Michael, Levy M.D.,Ph.D., Jazz Pharmaceuticals | NMO Spectrum Disorder, Spasticity, Muscle | 04/26 | 09/26 | | |
| Recruiting | 2 | 15 | Europe, US | Inebilizumab | Amgen, Horizon Therapeutics Ireland DAC | Neuromyelitis Optica Spectrum Disorder | 04/27 | 04/27 | | |
NCT00716066: Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases |
|
|
| Active, not recruiting | 2 | 53 | US | Anti-Thymocyte Globulin, Antithymocyte Globulin, Antithymocyte Serum, ATG, ATGAM, ATS, Thymoglobulin, Autologous Hematopoietic Stem Cell Transplantation, Autologous Stem Cell Transplantation, Carmustine, BCNU, Becenum, Becenun, BiCNU, Bis(chloroethyl) Nitrosourea, Bis-Chloronitrosourea, Carmubris, Carmustin, Carmustinum, FDA 0345, Gliadel, N,N'-Bis(2-chloroethyl)-N-nitrosourea, Nitrourean, Nitrumon, SK 27702, SRI 1720, WR-139021, 154-93-8, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosar-U, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, 147-94-4, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, 33419-42-0, Laboratory Biomarker Analysis, Melphalan, Alanine Nitrogen Mustard, CB-3025, L-PAM, L-Phenylalanine Mustard, L-Sarcolysin, L-Sarcolysin Phenylalanine mustard, L-Sarcolysine, Melphalanum, Phenylalanine Mustard, Phenylalanine Nitrogen Mustard, Sarcoclorin, Sarkolysin, WR-19813, 148-82-3, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, Peripheral Blood Progenitor Cell Transplantation, Peripheral Stem Cell Support, Peripheral Stem Cell Transplantation, Prednisone, .delta.1-Cortisone, 1, 2-Dehydrocortisone, Adasone, Cortancyl, Dacortin, DeCortin, Decortisyl, Decorton, Delta 1-Cortisone, Delta-Dome, Deltacortene, Deltacortisone, Deltadehydrocortisone, Deltasone, Deltison, Deltra, Econosone, Lisacort, Meprosona-F, Metacortandracin, Meticorten, Ofisolona, Orasone, Panafcort, Panasol-S, Paracort, PRED, Predicor, Predicorten, Prednicen-M, Prednicort, Prednidib, Prednilonga, Predniment, Prednisonum, Prednitone, Promifen, Servisone, SK-Prednisone, 53-03-2, Syngeneic Bone Marrow Transplantation | Fred Hutchinson Cancer Center | Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune, Multiple Sclerosis Transplant, MS Stem Cell Transplant, Multiple Sclerosis Stem Cell Transplant, Stiff Person Syndrome, HCT for Neurologic Autoimmune Disorders, CIDP Transplant, Myasthenia Gravis Transplant, Autoimmune Nervous System Disorder, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Lambert Eaton Myasthenic Syndrome, Myasthenia Gravis, Neuromyelitis Optica, Opsoclonus Myoclonus Syndrome, Rasmussen Subacute Encephalitis | 01/25 | 01/30 | | |
ChiCTR2000031254: Safety and pharmacokinetics of ACT001 Capsules for the treatment of patients with recurrent neuromyelitis optica spectrum disorder-related optic neuritis (NMOSD-ON) : an open-label, dose-escalation, phase I/IIa clinical study |
|
|
| Recruiting | 1/2 | 12 | | Subjects will receive single dose 100mg of ACT001 in the morning at Day 1 of Cycle 1, followed by a 48-hour washout period, and then receive consecutive treatment with ACT001 BID (100mg x 2times)since Day 3 till withdrawal from the study (30-day treatment period for Cycle 1, 28-day treatment period ;Subjects will receive single dose 200mg of ACT001 in the morning at Day 1 of Cycle 1, followed by a 48-hour washout period, and then receive consecutive treatment with ACT001 BID (200mg x 2times)since Day 3 till withdrawal from the study (30-day treatment period for Cycle 1, 28-day treatment period ;Subjects will receive single dose 400mg of ACT001 in the morning at Day 1 of Cycle 1, followed by a 48-hour washout period, and then receive consecutive treatment with ACT001 BID (400mg x 2times)since Day 3 till withdrawal from the study (30-day treatment period for Cycle 1, 28-day treatment period ;Subjects will receive single dose 600mg of ACT001 in the morning at Day 1 of Cycle 1, followed by a 48-hour washout period, and then receive consecutive treatment with ACT001 BID (600mg x 2times)since Day 3 till withdrawal from the study (30-day treatment period for Cycle 1, 28-day treatment period | The First Medical Center of PLA General Hospital; Accendatech Luoyang Co., Ltd., Some are funded by the government and others are self-funded | Recurrent NMOSD-ON | | | | |
| Completed | 1/2 | 14 | RoW | Belimumab | Tianjin Medical University General Hospital | NMO Spectrum Disorder | 06/23 | 04/24 | | |
NCT05792462: Efficacy and Safety of Baricitinib in Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 1/2 | 12 | RoW | Baricitinib | Tianjin Medical University General Hospital | NMO Spectrum Disorder | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 5 | RoW | Ofatumumab, Arzerra | Tang-Du Hospital, Henan Provincial People's Hospital | Neuromyelitis Optica Spectrum Disorder | 06/24 | 12/24 | | |
NCT05909943: Efficacy and Safety of Ruxolitinib in Neuromyelitis Optica Spectrum Disorders |
|
|
| Withdrawn | 1/2 | | RoW | Ruxolitinib | Tianjin Medical University General Hospital | Neuromyelitis Optica Spectrum Disorder Relapse | 02/26 | 08/26 | | |
ChiCTR1900027024: A Phase I Clinical Trial of BAT4406 Injection on the Safety, Tolerability and Pharmacokinetics in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 1 | 48 | | BAT4406F, 50mg, Intravenous infusion ;BAT4406F, 100mg, Intravenous infusion ;BAT4406F, other doses are to be administered depending on the circumstances, Intravenous infusion ;BAT4406F, 20mg, Intravenous infusion | Huashan Hospital affiliated to Fudan University; Bio-thera Solutions, Ltd., self-finance | Neuromyelitis Optica Spectrum Disorders | | | | |
ChiCTR2000029151: Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of HBM9161 weekly subcutaneous administration in patients with neuromyelitis optica spectrum disorders (NMOSD) in China. |
|
|
| Recruiting | 1 | 18 | | HBM9161 | The Third Affiliated Hospital, Sun Yat-Sen Unvierity; Harbour BioMed (Guangzhou) Co., Ltd, Harbour BioMed (Guangzhou) Co., Ltd | Neuromyelitis optica spectrum disorders | | | | |
| Completed | 1 | 70 | RoW | LP-168 tablet, NWP-775, LP-168 Placebo tablet, NWP-775 Placebo | Guangzhou Lupeng Pharmaceutical Company LTD. | Multiple Sclerosis, NMO Spectrum Disorder | 11/22 | 12/22 | | |
NCT04146285: A Phase I Clinical Trial of BAT4406F Injection in Patients With Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 1 | 15 | RoW | BAT4406F | Bio-Thera Solutions | Neuromyelitis Optica Spectrum Disorders | 03/23 | 06/23 | | |
NCT05145361: Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD) |
|
|
| Recruiting | 1 | 45 | RoW | B001 injection, Placebo | Shanghai Pharmaceuticals Holding Co., Ltd | NMO Spectrum Disorder | 12/24 | 12/24 | | |
CARTinNS, NCT04561557: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System |
|
|
| Recruiting | 1 | 36 | RoW | CT103A cells, Cyclophosphamide and fludarabine | Tongji Hospital, Nanjing IASO Biotechnology Co., Ltd. | Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Idiopathic Inflammatory Myopathies, Multiple Sclerosis, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), POEMS Syndrome | 02/27 | 05/27 | | |
CAR-AID, NCT06249438: A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy |
|
|
| Recruiting | 1 | 30 | RoW | CD20/BCMA-directed CAR-T cells, C-CAR168 | RenJi Hospital, AbelZeta Pharma Inc. | Systemic Lupus Erythematosus (SLE), Immune-Mediated Necrotizing Myopathy, Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis-Relapsing-Remitting | 03/27 | 03/40 | | |
ChiCTR2200057880: A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG positive neuromyelitis optica spectrum disorder |
|
|
| Not yet recruiting | 1 | 23 | | Orelabrutinib, orally, 50 mg QD | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Beijing InnoCare Pharma Tech Co., Ltd. | Neuromyelitis optica spectrum disorder | | | | |
NCT05828212: Evaluate the Safety and Efficacy of CAR-T Cells in the Treatment of R/R Neuromyelitis Optica |
|
|
| Recruiting | 1 | 9 | RoW | CD19 CAR-T cells injection | Zhejiang University | Neuromyelitis Optica | 04/26 | 04/26 | | |
| Not yet recruiting | N/A | 249 | | | Monash University, Monash University, F. Hoffmann-La Roche Ltd | Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder | | | | |
ACTRN12623001310651: Assisted Reproductive Technology in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders (ARTiMS) study. A prospective, longitudinal study. |
|
|
| Recruiting | N/A | 25 | | | John Hunter Hospital of the Hunter New England Local Health District, Merck Healthcare Pty. Ltd | Pregnancy, Multiple Sclerosis, sub-fertility, Neuromyelitis Optica Spectrum Disorders | | | | |
ChiCTR-RRC-17011755: The characteristics and immunology research of Neuromyelitis optica spectrum disorders |
|
|
| Recruiting | N/A | 60 | | Nil | Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, National and Fujian Province's key Clincial Specialty Discipline Construction Programs | Neuromyelitis optica spectrum disorders | | | | |
ChiCTR-ICR-15007177: A Prospective Study on the Efficacy andSafety of Rituximab in Treatment for Neuromyelitis Optica associated Optic Neuritis |
|
|
| Recruiting | N/A | 60 | | Intravenous 100mg Rituximab, 1/week*4 ;Oral azathioprine (2.5-3 mg/kg bodyweight/day) or mycophenolate mofetil (1000-1500mg/day) | The Ophthalmology Department of the Chinese Peoples Liberation Army Hospital; The Chinese Peoples Liberation Army Hospital, The National High Technology Research andDevelopment Program (No. 2015AA020511) | Neuromyelitis Optica associated Optic Neuritis | | | | |
| Recruiting | N/A | 7000 | RoW | Data collection and follow-up observation, Data collection | Xuanwu Hospital, Beijing | Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Myasthenia Gravis, Autoimmune Encephalitis, Acute Disseminated Encephalomyelitis | 12/24 | 12/24 | | |
ChiCTR1900020856: Correlation between the diversity of intestinal flora and the imaging characteristics of adult NMOSD based on 'Bacteria-intestine-brain' axis |
|
|
| Not yet recruiting | N/A | 60 | | Nil | Shenzhen Traditional Chinese Medicine Hospital; Shenzhen Traditional Chinese Medicine Hospital, Hospital Self-financing and Key Specialized Funds | neuromyelitis optica spectrum disorders,NMOSD | | | | |
ChiCTR1800016241: Prognosis Prediction Model for Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | N/A | 300 | | None | West China Hospital, Sichuan University; West China Hospital, Sichuan University, SCI funds of west China hospital of sichuan university | Neuromyelitis optica spectrum disorders | | | | |
ChiCTR2000037477: Investigation of GABA levels, changes in microstructure and function and relation with cognitive impairment in patients with NMOSD: a multimodal MRI study |
|
|
| Not yet recruiting | N/A | 60 | | Nil ;Nil | Department of Radiology, the First Affiliated Hospital of Soochow University; the First Affiliated Hospital of Soochow University, National Natural Science Foundation of China (No.81671743) | NMOSD | | | | |
ChiCTR1800019275: Efficacy and Safety of Autologous Hematopoietic Stem Cell Transplantation (AHSCT) in aggressive multiple sclerosis and neuromyelitis optica |
|
|
| Recruiting | N/A | 160 | | autologous peripheral hematopoietic stem cell transplantation (CD34+) ;The most effective drugs treatment for individuals of the time | Xuanwu Hospital, Capital Medical University; Xuanwu Hospital, Capital Medical University, IIR，Investigator Initiated Research | Idiopathic inflammatory demyelinating diseases (multiple sclerosis, neuromyelitis optica)) | | | | |
| Recruiting | N/A | 3000 | | no intervention ;no intervention | West China Hospital, Sichuan University; West China Hospital, Sichuan University, the National Key Basic Research and Development Program of China (No. 2017YFC0907704) | Neuromyelitis optic spectrum disoders (NMOSD), multiple sclerosis(MS), myasthenia gravis(MG), and guillain-barre syndrome(GBS) | | | | |
ChiCTR2100052936: The establishment of metabolic fingerprints-aided diagnostic model of neuromyelitis optica spectrum disorder |
|
|
| Not yet recruiting | N/A | | | | Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, researcher initiated | Neuromyelitis Optica Spectrum Disorders | | | | |
| Not yet recruiting | N/A | 300 | | no | Department of Neurology of Beijing Tongren Hospital, Capital Medical University; Beijing Tongren Hospital, Capital Medical University, Research Fund of Hosptial | NMOSD | | | | |
| Not yet recruiting | N/A | 240 | | Nil | Huashan Hospital, Fudan University; Huashan Hospital, National Natural Science Foundation of China | NMOSD | | | | |
ChiCTR2000036285: A Recombinant Human B Lymphocyte Stimulator Receptor-Immunoglobulin G (IgG ) Fc Fusion Protein in the Treatment of Subjects with Neuromyelitis Optica Spectrum Disorders: a Single Center, Randomized, Controlled Clinical Study |
|
|
| Not yet recruiting | N/A | 60 | | plasma exchange and Telitacicept ;plasma exchange and placebo | Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Level of the institution：, Shanghai Shenkang Hospital Development Center | Neuromyelitis Optica Spectrum Disorders | | | | |
ChiCTR-INR-16008037: Treatment of hUC-MSC for neuromyelitis optica spectrum disorder- A prospective multicenter randomized controlled study |
|
|
| Not yet recruiting | N/A | 480 | | regular drug treatment plus hUC-MSC ;regular drug treatment plus placebo | Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University; Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Found from multi-center clinical trial of School of Medicine, Shanghai Jiao Tong University | neuromyelitis optica spectrum disorder | | | | |
NCT04106830: Clinical and Imaging Patterns of Neuroinflammation Diseases in China (CLUE) |
|
|
| Recruiting | N/A | 1000 | RoW | Intravenous steroid, Azathioprine, Mycophenolate Mofetil, Rituximab | Beijing Tiantan Hospital | NMO Spectrum Disorder, MRI, Multiple Sclerosis | 12/22 | 12/25 | | |
NCT05070286: Lifestyle Weight Management Program: Interviews and Stakeholder Meetings. |
|
|
| Recruiting | N/A | 45 | Europe | Observational Study. | Oxford Brookes University, Great Ormond Street Hospital for Children NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust, Oxford University Hospitals NHS Trust | Multiple Sclerosis, Neuromyelitis Optica | 12/22 | 12/22 | | |
ChiCTR2200066921: The application of molecular imaging for the assessment of neuroinflammation in patients with NMOSD and MOG-AD |
|
|
| Recruiting | N/A | | | | Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Renji-United Imaging 2021 Clinical Research Innovation Incubation Project | Neuromyelitis Optica Spectrum Disorders and Myelin oligodendrocyte glycoprotein antibody disease | | | | |
NCT05871658: Efficacy of Electroacupuncture in NMOSD Patients With Pain: Study Protocol |
|
|
| Completed | N/A | 20 | RoW | electroacupuncture | Yuanqi Zhao,MD | Neuromyelitis Optica Spectrum Disorders, Pain | 02/23 | 02/23 | | |
SONICS, NCT03942952: PEDIATRIC Pediatric Study of Neuropsychology and Imaging in CNS Demyelinating Syndromes. |
|
|
| Completed | N/A | 49 | US | | University of Texas Southwestern Medical Center | Multiple Sclerosis, Relapsing-Remitting, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Transverse Myelitis | 06/23 | 06/23 | | |
ChiCTR2100051105: Correlation between IMPDH and SLCO1B polymorphisms and the efficacy and safety of mycophenolate mofetil in patients with neuromyelitis optica spectrum disorders |
|
|
| Recruiting | N/A | 200 | | MMF treatment | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, National Science Foundation for Youth Scientists of China (Grant No. 81703613) | Neuromyelitis optica spectrum disorders (NMOSD) | | | | |
ChiCTR2300074346: The predictive role of serum albumin in the treatment of acute stage of optic nerve Myelitis spectrum diseases |
|
|
| Completed | N/A | 86 | | NONE ;NONE | Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, NONE | Neuromyelitis Optica Spectrum Disorders | | | | |
NCT05284175: A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder |
|
|
| Not yet recruiting | N/A | 23 | RoW | Orelabrutinib | Peking Union Medical College Hospital, Beijing InnoCare Pharma Tech Co., Ltd., GCP ClinPlus Co., Ltd. | Neuromyelitis Optica Spectrum Disorder | 08/23 | 08/23 | | |
ChiCTR2300070749: Observing the clinical efficacy of Lingnan herbal medicine combined with traditional Chinese medicine spleen-tonifying and kidney-nourishing method on NMO/NMOSD from the perspective of the 'microbiota-gut-brain' axis in a real-world study |
|
|
| Recruiting | N/A | 99 | | Lingnan herbal medicine combined with spleen-tonifying and kidney-nourishing traditional Chinese medicine plus Western medicine treatment ;Western medicine treatment | Shenzhen Traditional Chinese Medicine Hospital The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine; Shenzhen Traditional Chinese Medicine Hospital, Allocation of Funds from Superior Authorities and Hospital Matching | Neuromyelitis optica/Neuromyelitis optica spectrum disorders | | | | |
OMNISCIENT, NCT05414487: Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases |
|
|
| Recruiting | N/A | 34 | RoW | Ofatumumab | Tianjin Medical University General Hospital | Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Demyelinating Diseases of the Central Nervous System | 12/23 | 06/24 | | |
| Completed | N/A | 11 | Europe | CSO_without cueing, CSO_cueing | University Ghent | Gait, Festinating, Parkinson Disease, Device Adherence | 05/24 | 05/24 | | |
NCT05840055: ACT With NMOSD Patients and Caregivers Pilot Study |
|
|
| Recruiting | N/A | 50 | US | Acceptance and Commitment Therapy | Thomas Jefferson University, Alexion Pharmaceuticals, Inc. | NMO Spectrum Disorder | 06/24 | 09/24 | | |
| Completed | N/A | 100 | US | | Mayo Clinic, Alexion Pharmaceuticals, Inc. | Neuromyelitis Optica, NMO Spectrum Disorder | 04/24 | 04/24 | | |
NCT04629274: In Vitro Study of the Biological and Immunological Activity of Imotopes® Candidates on Blood Cells of Patients With Stabilized NMO |
|
|
| Completed | N/A | 15 | Europe | Blood sampling | Imcyse SA | Neuromyelitis Optica | 06/24 | 06/24 | | |
OPTIS, NCT05566769: Performance and Safety of a Digital Tool for Unsupervised Self-assessment of NMOSD |
|
|
| Recruiting | N/A | 103 | Europe, US | NMOSDCopilot smartphone application | Ad scientiam | Neuromyelitis Optica | 11/24 | 07/25 | | |
RECLAIM, NCT06280755: Clinical Impact Through AI-assisted MS Care - A Retrospective Multi-center Observational Study. |
|
|
| Not yet recruiting | N/A | 7000 | NA | | icometrix, Charite University, Berlin, Germany, Ruhr University of Bochum, Technische Universität Dresden, University Hospital, Lille, Casa di Cura IGEA, General University Hospital, Prague, Hoffmann-La Roche, Bristol-Myers Squibb, Imcyse SA, AB Science, Nocturne UG, Aalto University | Multiple Sclerosis, NMO Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Radiologically Isolated Syndrome, Clinically Isolated Syndrome | 04/27 | 04/27 | | |
NCT06312644: Study of Ultomiris® (Ravulizumab) Safety in Pregnancy |
|
|
| Not yet recruiting | N/A | 300 | NA | Ultomiris, There is no interventional drug. Ultomiris treatment is an inclusion criterion. | Alexion Pharmaceuticals, Inc. | Ultomiris-exposed Pregnant/ Postpartum, Pregnancy, Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (aHUS), Generalized Myasthenia Gravis (gMG), Neuromyelitis Optica Spectrum Disorder (NMOSD) | 10/33 | 10/33 | | |
| Recruiting | N/A | 150 | Europe | Neuro-ophtalmology examination | University Hospital Center of Martinique, University Hospital Center of Guadeloupe, Hospital Center of Cayenne (French Guyana) | Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis | 06/24 | 06/25 | | |
aNiMatO, NCT06374264: Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder |
|
|
| Not yet recruiting | N/A | 30 | US | MR-C-014 | MedRhythms, Inc., Alexion Pharmaceuticals, Inc. | Neuromyelitis Optica Spectrum Disorder | 12/24 | 12/24 | | |
NCT06068829: Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | N/A | 80 | NA | Inebilizumab, Rituximab(RTX) | Feng Jinzhou | Neuromyelitis Optica Spectrum Disorders | 06/24 | 06/25 | | |
NCT06474520: Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD) |
|
|
| Not yet recruiting | N/A | 250 | RoW | Calculus bovis sativus (CBS) | Tongji Hospital, Wuhan Jianmin DAPENG Pharmaceutical Co., Ltd. | Idiopathic Inflammatory Demyelinating Disease, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Acute Disseminated Encephalomyelitis | 07/29 | 12/29 | | |
AMAZE, NCT06398158: Study of the Clinical and Radiological Impact of Ravulizumab in People With Neuromyelitis Optica Spectrum Disorder |
|
|
| Recruiting | N/A | 35 | US | Ravulizumab | University of Texas Southwestern Medical Center, Alexion Pharmaceuticals, Inc. | Neuromyelitis Optica | 12/26 | 06/27 | | |
ChiCTR2200058626: A randomized controlled study of repeated transcranial magnetic stimulation (rTMS) combined with drugs to improve neuropathic pain in neuromyelitis optica spectrum disease |
|
|
| Not yet recruiting | N/A | 40 | | NMOSDs conventional drug therapy +rTMS treatment group (experimental group) ;conventional drug therapy | Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Key Specialty fund of Union Hospital affiliated to Fujian Medical University | Neuromyelitis optic spectrum disease | | | | |
ChiCTR2200059612: The cognitive function and image and quality of life and lymphocyte research of Neuromyelitis optica spectrum disorders |
|
|
| Not yet recruiting | N/A | 90 | | none ;none ;none | Fujian Medical University Union Hospital; Fujian Medical University Union Hospital, Supported by key Specialty of FuJian Medical University | Neuromyelitis optica spectrum disorders | | | | |
NCT06118398: Efgartigimod in Acute Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | N/A | 24 | NA | Intravenous methylprednisolone (IVMP) and Efgartigimod, IVMP | Feng Jinzhou | Neuromyelitis Optica, Efgartigimod | 11/24 | 05/25 | | |
ChiCTR2100052163: Multimodal spinal magnetic resonance to explore quantitative evaluation and intramedullary mechanism of neuromyelitis optica spectrum disorder with painful tonic spasm |
|
|
| Not yet recruiting | N/A | 60 | | None ;None ;None | Shanghai Jing'an District Central Hospital; Shanghai Jing'an District Central Hospital, self-funded | neuromyelitis optica spectrum disorder | | | | |
NCT01623076: The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders |
|
|
| Recruiting | N/A | 150 | US | | University of Texas Southwestern Medical Center | Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Optic Neuritis | 06/25 | 06/25 | | |
NCT05891379: Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | N/A | 50 | NA | Inebilizumab, oral immunosuppressant | Xuanwu Hospital, Beijing, Jiangsu Hansoh Pharmaceutical Co., Ltd. | Neuromyelitis Optica Spectrum Disorder | 07/25 | 07/25 | | |
ChiCTR1800019427: A Recombinant Human B Lymphocyte Stimulator Receptor-Immunoglobulin G (IgG ) Fc Fusion Protein Injection in the Treatment of Subjects With Recurrent Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | N/A | 8 | | Plasma exchange + a Recombinant Human B Lymphocyte Stimulator Receptor:Immunoglobulin G( IgG ) Fc Fusion Protein for Injection | Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Yantai Rongchang Pharmaceutical Co.,Ltd. | Neuromyelitis Optica Spectrum Disorders | | | | |
ChiCTR2300074292: Differences between mycophenolate mofetil and azathioprine in prevention of recurrence of Neuromyelitis Optica Spectrum Disorders and analysis of influencing factors |
|
|
| Recruiting | N/A | 100 | | N/A ;N/A | Renji Hospital, School of Medicine, Shanghai Jiao Tong University; Renji Hospital, School of Medicine, Shanghai Jiao Tong University, None | Neuromyelitis Optica Spectrum Disorders | | | | |
ChiCTR2300073677: High throughput multimodal study of the clinical phenotype of NMOSD |
|
|
| Recruiting | N/A | 180 | | N/A ;N/A ;NA | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, Investigator | nervous system autoimmune diseases | | | | |
NCT00445367: Biobank For MS And Other Demyelinating Diseases |
|
|
| Active, not recruiting | N/A | 3226 | US | | Accelerated Cure Project for Multiple Sclerosis | Multiple Sclerosis, Transverse Myelitis, Neuromyelitis Optica, Acute Disseminated Encephalomyelitis, Optic Neuritis | 10/26 | 10/36 | | |
| Recruiting | N/A | 10000 | RoW | Intravenous steroid, Immunoglobulin, Immunosuppressive Drugs, Disease-Modifying Drugs | Beijing Tiantan Hospital | Multiple Sclerosis, NMO Spectrum Disorder, Clinically Isolated Syndrome, CNS Demyelinating Autoimmune Diseases, Acute Disseminated Encephalomyelitis, Primay Angiitis of the Central Nervous System, Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy | 11/26 | 11/26 | | |
NCT05966467: Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies |
|
|
| Recruiting | N/A | 122 | US | | Alexion Pharmaceuticals, Inc. | Neuromyelitis Optica Spectrum Disorder, NMOSD, AQP4+ NMOSD | 09/26 | 09/26 | | |
NCT05982925: Longitudinal Cortical Demyelination in Multiple Sclerosis and Related Disorders |
|
|
| Recruiting | N/A | 100 | US | | Icahn School of Medicine at Mount Sinai | Multiple Sclerosis, Neuromyelitis Optica, Demyelinating Autoimmune Diseases, CNS | 05/30 | 05/30 | | |
| Recruiting | N/A | 1000 | Europe, RoW | No intervention | Hospices Civils de Lyon | Sclerosis, Multiple, Neuromyelitis Optica Spectrum Disorder, Myelin Oligodendrocyte Glycoprotein (MOG)-Antibody Related Disorders, Pregnancy Abnormal | 08/36 | 08/36 | | |
NCT05004493: Biorepository and Registry for Plasma Exchange Patients |
|
|
| Recruiting | N/A | 200 | US | | Charles M Knudson | Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, CIDP | 12/30 | 12/40 | | |
NCT05909761: Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregnancy |
|
|
| Recruiting | N/A | 60 | US | UPLIZNA, inebilizumab-cdon | Amgen | Neuromyelitis Optica Spectrum Disorder, Pregnancy Related | 08/32 | 08/32 | | |
| Recruiting | N/A | 1000 | US | | Cedars-Sinai Medical Center | Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive, Clinically Isolated Syndrome, Radiologically Isolated Syndrome, Neuromyelitis Optica Spectrum Disorders, Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease, Neurologic Autoimmune Disease, Neurologic Disorder, Healthy Aging | 11/41 | 11/41 | | |
NCT05017142: Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD) |
|
|
| Recruiting | N/A | 500 | Europe | | University of Bern, Schweizerische Multiple Sklerose Gesellschaft, University Hospital Inselspital, Berne, Roche Pharma (Switzerland) Ltd, Novartis | Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Anti-NMDAR Encephalitis, Anti-GAD65 Associated Autoimmune Encephalitis, Anti-AMPAR-1/2 Associated Autoimmune Encephalitis, Anti-Lgi-1 Associated Autoimmune Encephalitis, Anti-CASPR-2 Associated Autoimmune Encephalitis, Anti-GABAR-1/2 Associated Autoimmune Encephalitis, Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis, Hashimoto Encephalitis, CNS Vasculitis, CNS Sarcoidosis, CNS Lupus, Rasmussen Encephalitis | 01/71 | 01/71 | | |
NCT04886492: CorEvitas SPHERES (Synergy of Prospective Health & Experimental Research for Emerging Solutions) Registry for Neuromyelitis Optica Spectrum Disorder (NMOSD) |
|
|
| Enrolling by invitation | N/A | 800 | US | | CorEvitas | Neuromyelitis Optica Spectrum Disorder | 01/99 | 01/99 | | |